Published in World J Urol on January 01, 1997
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol (1976) 4.37
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med (1991) 2.07
Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol (1986) 2.01
Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol (1984) 1.52
Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst (1972) 1.48
Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am (1992) 1.33
Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol (1987) 1.33
Intra-urothelial cancer: carcinoma in situ, Bowen's disease of the urinary system: discussion of thirty cases. J Urol (1952) 1.23
Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol (1990) 1.20
Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. J Urol (1996) 1.19
Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer (1980) 1.15
Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. A collaborative study of the five Nordic Cancer Registries. APMIS Suppl (1993) 1.07
Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol (1987) 0.95
Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol (1988) 0.93
Bladder cancer immunotherapy. J Urol (1982) 0.93
Independent clinical, histological and quantitative prognostic factors in transitional-cell bladder tumours, with special reference to mitotic frequency. Int J Cancer (1992) 0.90
Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol (1993) 0.90
Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol Res (1992) 0.86
Impact of tumour grade, stage, number and size, and smoking and sex, on survival in patients with transitional cell carcinoma of the bladder. Br J Urol (1995) 0.85
Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer. J Cancer Res Clin Oncol (1995) 0.85
Review of Mayo Clinic experience with carcinoma in situ. Urology (1985) 0.84
Statistical and epidemiologic data on urologic cancer. Cancer (1987) 0.81
Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur Urol (1991) 0.81
Urothelial dysplasia concomitant with bladder tumours as a determinant factor for future new occurrences. Lancet (1983) 0.80
Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol (1995) 0.80
Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. Br J Urol (1987) 0.79
Adriamycin instillations as recurrence prophylaxis in superficial urinary bladder cancer. Ann Chir Gynaecol (1984) 0.79
Immunotherapy of murine transitional cell carcinoma. J Urol (1982) 0.77
Expression of MIB-1, mitotic index and S-phase fraction as indicators of cell proliferation in superficial bladder cancer. Finnbladder Group. Urol Res (1996) 0.77
Intravesical instillation of Adriamycin. A model for standardization of the chemotherapy. Eur Urol (1980) 0.77
The absorption of doxorubicin and mitomycin C in perioperative instillation. An experimental and clinical study. Eur Urol (1985) 0.77
Intravesical cytostatics: pH-dependence of antitumour activity. Urol Res (1985) 0.77
Detecting mitomycin C in human plasma during intravesical therapy. Int Urol Nephrol (1985) 0.77
Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Finnbladder III Group. Urol Res (1997) 0.76
Cytostatic effect of interferon alpha on human bladder cancer cells in vitro. A flow cytometric study. Ann Chir Gynaecol Suppl (1993) 0.76
Surgery and intravesical chemotherapy in the management of superficial bladder cancer. Semin Urol (1983) 0.76
Transitional cell carcinoma: an overview. Urol Clin North Am (1980) 0.76
Bacillus Calmette-Guérin sensitises fresh transitional carcinoma cells and T24 cell line to non-MHC-restricted cytotoxicity in vitro. Br J Urol (1993) 0.76
Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study. Eur Urol (1986) 0.76
Biologic response modifiers in genitourinary neoplasia. Cancer (1987) 0.76
Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer. Arch Esp Urol (1990) 0.76
Optimising mitomycin C activity during intravesical instillation. Urol Res (1983) 0.76
Instillation therapy in superficial urinary bladder cancer. Finnbladder Group. Scand J Urol Nephrol Suppl (1991) 0.76
BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial. Urology (1988) 0.76
[European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract]. Actas Urol Esp (2011) 1.59
Role of orchiectomy in severe testicular pain after inguinal hernia surgery: audit of the Finnish Patient Insurance Centre. Hernia (2013) 1.53
Epidemiology and traumatology of injuries in elite soccer: a prospective study in Finland. Scand J Med Sci Sports (1996) 1.32
Acute appendicitis in the aged patient. Study of 300 cases after the age of 60. Arch Surg (1970) 1.27
Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. J Urol (1996) 1.19
Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer (1992) 1.18
Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol (2000) 0.93
Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer. Urology (2001) 0.91
Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol (1999) 0.91
Independent clinical, histological and quantitative prognostic factors in transitional-cell bladder tumours, with special reference to mitotic frequency. Int J Cancer (1992) 0.90
Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol (1992) 0.88
Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol Res (2000) 0.86
Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol Res (1992) 0.86
Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer. Int J Cancer (1993) 0.84
Spontaneous peripelvic extravasation of urine as a cause of acute abdomen. Scand J Urol Nephrol (1993) 0.84
Occupational exposure to chemical agents in the paper industry. Int Arch Occup Environ Health (2004) 0.82
Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur Urol (1991) 0.81
Grading of superficial bladder cancer by quantitative mitotic frequency analysis. J Urol (1993) 0.80
Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol (1995) 0.80
Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. Br J Urol (1987) 0.79
[EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. Actas Urol Esp (2012) 0.79
Central hypotensive effects of angiotensin II in the rat. Acta Med Scand Suppl (1976) 0.79
Adriamycin instillations as recurrence prophylaxis in superficial urinary bladder cancer. Ann Chir Gynaecol (1984) 0.79
Clinical prognostic factors in transitional cell cancer of the bladder. Urol Int (1993) 0.78
Exposure to monoterpenes in Finnish sawmills. Am J Ind Med (1999) 0.77
Prognostic factors in WHO grade 2 transitional-cell bladder cancer (TCC); a novel two-grade classification system for TCC based on mitotic index. J Cancer Res Clin Oncol (1992) 0.77
The absorption of doxorubicin and mitomycin C in perioperative instillation. An experimental and clinical study. Eur Urol (1985) 0.77
Detecting mitomycin C in human plasma during intravesical therapy. Int Urol Nephrol (1985) 0.77
Intravesical cytostatics: pH-dependence of antitumour activity. Urol Res (1985) 0.77
Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study. Eur Urol (1986) 0.76
Optimising mitomycin C activity during intravesical instillation. Urol Res (1983) 0.76
Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer. Arch Esp Urol (1990) 0.76
Prognostic utility of human complement factor H related protein test (the BTA stat Test). Br J Cancer (2001) 0.75
Prediction of superficial bladder cancer by nuclear image analysis. Eur J Cancer (1992) 0.75
Can fine needle aspiration biopsy detect incidental prostatic carcinoma (T1) prior to TUR? Eur Urol (1992) 0.75
Prognostic factors in nodular transitional cell bladder tumours. Scand J Urol Nephrol (1993) 0.75
[Nonparasitic splenic cysts]. Duodecim (1967) 0.75
Ceftazidime vs. tobramycin for serious infections in urological patients. J Hosp Infect (1990) 0.75
[Spontaneous rupture of the liver caused by hepatoma]. Duodecim (1985) 0.75
Independent prognostic factors in T2/T3 transitional cell bladder tumours with special reference to histoquantitative methods. Surg Oncol (1992) 0.75
Evaluation of communication device: an aphasia case study. Stud Health Technol Inform (1998) 0.75
The dilemma of suspicious urine cytology in patients being followed for bladder cancer. Ann Chir Gynaecol (2001) 0.75
[Fournier's gangrene--fulminant inflammation of the urogenital tract]. Duodecim (1990) 0.75
Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group. Prog Clin Biol Res (1989) 0.75
Proliferation indices as independent prognostic factors in papillary Ta-T1 transitional cell bladder tumours. Br J Urol (1993) 0.75
No genetic evidence of sex-biased dispersal in a lekking bird, the capercaillie (Tetrao urogallus). J Evol Biol (2007) 0.75
Characterization and control of terpene emissions in Finnish sawmills. AIHAJ (2001) 0.75
Clinical follow-up. Prog Clin Biol Res (1986) 0.75
Methodologies for quantifying the results of intravesical chemotherapy of superficial tumors of the bladder. Med Oncol Tumor Pharmacother (1985) 0.75
[Metronidazole prophylaxis in excision of the appendix]. Duodecim (1982) 0.75